CoChat

The NRF 2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis

Open access
Hammer, Anna, Waschbisch, Anne, Kuhbandner, Kristina, Bayas, Antonios, Lee, De‐Hyung, Duscha, Alexander, Haghikia, Aiden, Gold, Ralf, Linker, Ralf A. · 2018 · Annals of Clinical and Translational Neurology
Cited by 100

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objective: Immunological studies have demonstrated a plethora of beneficial effects of dimethyl fumarate (DMF) on various cell types. However, the cellular and molecular targets are incompletely understood and response markers are scarce. Here, we focus on the relation between nuclear factor (erythroid‐derived 2)‐like 2 (NRF 2) pathway induction under DMF therapy and the composition of the blood immune cell compartment and clinical efficacy in relapsing‐remitting multiple sclerosis (MS) patients. Methods: We explored effects of DMF on peripheral immune cell subsets by flow cytometric and transcriptional analysis of serial blood samples obtained from 43 MS patients during the first year of therapy. Results: Gene expression analysis proved activation of NRF 2 signaling under DMF therapy that was paralleled by a temporal expansion of FoxP3+ regulatory T cells, CD 56 bright natural killer cells, plasmacytoid dendritic cells, and a decrease in CD 8+ T cells, B cells, and type 1 myeloid dendritic cells. In a subgroup of 28 patients with completely available clinical data, individuals with higher levels of the NRF 2 target gene NAD(P)H quinone dehydrogenase 1 (NQO 1) 4–6 weeks after DMF therapy initiation were more likely to achieve no evidence of disease activity status 1 year later. The degree of NQO 1 induction further correlated with patient age. Interpretation: We demonstrate that positive effects of DMF on the clinical outcome are paralleled by induction of the antioxidant NRF 2 transcriptional pathway and a shift toward regulatory immune cell subsets in the periphery. Our data identify a role of the NRF 2 pathway as potential biomarker for DMF treatment in MS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acn3.553

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 100

Metadata

Authors
Hammer, A., Waschbisch, A., Kuhbandner, K., Bayas, A., Lee, D., Duscha, A., Haghikia, A., Gold, R., & Linker, R. A.
Venue
Annals of Clinical and Translational Neurology
Publisher
Wiley
Published
2018-04-16
Volume
5
Issue
6
Pages
668-676
ISSN
2328-9503 (ISSN-L)
OpenAlex
W2801318738
Cited by
100
References
6
FWCI
5.62
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The NRF 2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis. https://app.cochat.ai/papers/10.1002/acn3.553
The paper
Hammer, A., Waschbisch, A., Kuhbandner, K., Bayas, A., Lee, D., Duscha, A., Haghikia, A., Gold, R., & Linker, R. A. (2018). The NRF 2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.553

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.